Patents in genetic engineering and computer...
- Published in:
- International Review of Law, Computers & Technology, 1997, v. 11, n. 2, p. 318
- Publication type:
- Article
Works matching DE "BIOGEN Inc. (1978-2003)"
Results: 22
1
2
RECOMBINATION.
- Published in:
- Bio-IT World, 2003, v. 2, n. 8, p. 18
- Publication type:
- Article
3
EDC SHREDS PAPER TRAILS.
- Published in:
- Bio-IT World, 2003, v. 2, n. 4, p. 1
- By:
- Publication type:
- Article
4
Contest in prospect over interferon rights.
- Published in:
- Nature, 1985, p. 207, doi. 10.1038/314207a0
- By:
- Publication type:
- Article
5
The commercialization of molecular biology: Walter Gilbert and the Biogen startup.
- Published in:
- History & Technology, 2017, v. 33, n. 1, p. 126, doi. 10.1080/07341512.2017.1338554
- By:
- Publication type:
- Article
6
Patent Watch.
- Published in:
- Nature Reviews Drug Discovery, 2003, v. 2, n. 9, p. 690, doi. 10.1038/nrd1188
- Publication type:
- Article
7
Options for multiple sclerosis therapy.
- Published in:
- JAMA: Journal of the American Medical Association, 1994, v. 272, n. 18, p. 1393, doi. 10.1001/jama.1994.03520180017006
- By:
- Publication type:
- Article
8
Profile: Julian Davies.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 7, p. 727, doi. 10.1038/nbt0708-727
- By:
- Publication type:
- Article
9
Biotechs sue Columbia over fourth Axel patent.
- Published in:
- Nature Biotechnology, 2003, v. 21, n. 9, p. 955, doi. 10.1038/nbt0903-955
- By:
- Publication type:
- Article
10
First biotech drug to treat psoriasis.
- Published in:
- Nature Biotechnology, 2002, v. 20, n. 7, p. 640, doi. 10.1038/nbt0702-640
- By:
- Publication type:
- Article
11
Monstrous crowing.
- Published in:
- 2001
- Publication type:
- Editorial
12
Biogen antibody may not be immune to side effects.
- Published in:
- Nature Biotechnology, 1999, v. 17, n. 12, p. 1147, doi. 10.1038/70657
- By:
- Publication type:
- Article
13
EPO verdict lifts patent coverage of seeds.
- Published in:
- Nature, 1995, v. 374, n. 6517, p. 8, doi. 10.1038/374008a0
- By:
- Publication type:
- Article
14
More patent troubles about genes.
- Published in:
- Nature, 1994, v. 372, n. 6506, p. 485, doi. 10.1038/372485a0
- Publication type:
- Article
15
House of Lords is asked to rule on breadth of gene patent coverage.
- Published in:
- Nature, 1994, v. 372, n. 6506, p. 487, doi. 10.1038/372487a0
- By:
- Publication type:
- Article
16
Alefacept: Amevive, BG 9273, Human LFA-3/Igg Fusion Protein, LFA 3, LFA 3 TIP, LFA 3/CD2, LFA-3/Igg Fusion Protein, LFA3TIP, Recombinant LFA-3/Igg1 Human Fusion Protein, Recombinantly Engineered LFA-1/Igg1 Human Fusion Protein.
- Published in:
- Drugs in R&D, 2002, v. 3, n. 1, p. 21, doi. 10.2165/00126839-200203010-00004
- Publication type:
- Article
17
Biogen and immune disease.
- Published in:
- Nature, 1999, v. 402, n. 6763, p. 48, doi. 10.1038/35005549
- By:
- Publication type:
- Article
18
Accessing the abcs.
- Published in:
- Inside MS, 2000, v. 18, n. 1, p. 50
- By:
- Publication type:
- Article
19
Training in self injection is essential.
- Published in:
- Inside MS, 1996, v. 14, n. 3, p. 6
- Publication type:
- Article
20
Conference call helps answer Avonex question.
- Published in:
- Inside MS, 1996, v. 14, n. 3, p. 5
- Publication type:
- Article
21
FDA approval sought for Avonex.
- Published in:
- Inside MS, 1995, v. 13, n. 3, p. 9
- Publication type:
- Article
22
New Products.
- Published in:
- 2003
- Publication type:
- Product Review